The Effects of Estrone (Ogen) on Spinal Bone Density of Postmenopausal Women

Steven T. Harris, Harry K. Genant, David J. Baylink, J. Christopher Gallagher, Sherry Katz Karp, Maureen A. Mcconnell, Elizabeth M. Green, Ralph W. Stoll

Research output: Contribution to journalArticle

53 Scopus citations

Abstract

The effects of cyclical treatment with estrone sulfate (0.3, 0.625, or 1.25 mg), plus calcium carbonate, on spinal trabecular bone density were compared with placebo in 120 postmenopausal women in this 2-year, multicenter, doubleblind study. While the placebo and 0.3-mg treatment groups lost bone density (-3.6% and -5.1%), the 0.625- and 1.25-mg treatment groups experienced no significant change from baseline at 24 months (-0.8% and +0.7%). The 1.25-mg treatment group was significantly different from the placebo group at 12,18, and 24 months. Although the 0.625-mg treatment group was significantly different from the placebo group only at 18 months, the data suggest that 0.625 and 1.25 mg of estrone sulfate had different effects than placebo and 0.3 mg of estrone sulfate and, given with supplemental calcium, are effective doses for the prevention of spinal bone loss.

Original languageEnglish (US)
Pages (from-to)1980-1984
Number of pages5
JournalArchives of Internal Medicine
Volume151
Issue number10
DOIs
StatePublished - Oct 1991

All Science Journal Classification (ASJC) codes

  • Internal Medicine

Fingerprint Dive into the research topics of 'The Effects of Estrone (Ogen) on Spinal Bone Density of Postmenopausal Women'. Together they form a unique fingerprint.

  • Cite this

    Harris, S. T., Genant, H. K., Baylink, D. J., Gallagher, J. C., Karp, S. K., Mcconnell, M. A., Green, E. M., & Stoll, R. W. (1991). The Effects of Estrone (Ogen) on Spinal Bone Density of Postmenopausal Women. Archives of Internal Medicine, 151(10), 1980-1984. https://doi.org/10.1001/archinte.1991.00400100060010